^
    Apply
    A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer (NCT07150403)
    Phase 2
    Federation Francophone de Cancerologie Digestive
    Not yet recruiting
    Last update posted :
    09/02/2025
    Initiation :
    12/31/2025
    Primary completion :
    02/28/2028
    Completion :
    10/31/2028
    BRAF
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium
    Digoxin Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients (NCT07025850)
    Phase 1/2
    Fudan University
    Not yet recruiting
    Last update posted :
    06/18/2025
    Initiation :
    08/01/2025
    Primary completion :
    01/01/2027
    Completion :
    05/01/2027
    PD-L1
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (NCT06856837)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Not yet recruiting
    Last update posted :
    03/04/2025
    Initiation :
    04/01/2025
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    BRAF
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (ST316-101) (NCT05848739)
    Phase 1
    Sapience Therapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    PD-L1 • MSI • BRCA
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium • Lonsurf (trifluridine/tipiracil) • ST316
    Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer (NCT06791083)
    Phase 2
    First Affiliated Hospital of Fujian Medical Uni...
    Recruiting
    Last update posted :
    01/24/2025
    Initiation :
    06/20/2024
    Primary completion :
    12/01/2025
    Completion :
    05/01/2027
    CD8 • CD31 • PECAM1
    |
    Fruzaqla (fruquintinib) • Enweida (envafolimab)
    A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma (NCT06553781)
    Phase N/A
    Fudan University
    Not yet recruiting
    Last update posted :
    08/14/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    BRAF
    |
    Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)
    ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer (NCT06543836)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    08/08/2024
    Initiation :
    12/01/2023
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    BRAF
    |
    Tyvyt (sintilimab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib)
    Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas (NCT05565417)
    Phase 1/2
    Immunitas Therapeutics
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    11/28/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    KRAS • BRAF • ALK • PIK3CA • MET • MSI
    |
    BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation
    |
    Fruzaqla (fruquintinib) • rezorstobart (IMT-009)
    : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors (NCT03903705)
    Phase 1/2
    Hutchmed
    Recruiting
    Last update posted :
    04/25/2024
    Initiation :
    04/25/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    PD-L1 • ALK • ROS1 • IFNA1
    |
    PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression (HCCSC-C03) (NCT05661357)
    Phase 4
    Zhongnan Hospital
    Active, not recruiting
    Last update posted :
    04/17/2024
    Initiation :
    01/01/2023
    Primary completion :
    01/31/2025
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression
    |
    Aidixi (disitamab vedotin) • Fruzaqla (fruquintinib)
    Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment (SALVLIV) (NCT06199232)
    Phase N/A
    Peking University
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    01/23/2024
    Primary completion :
    01/23/2026
    Completion :
    01/23/2027
    BRAF
    |
    Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib)
    Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer (NCT05522738)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    01/08/2024
    Initiation :
    08/10/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    RAS
    |
    RAS mutation
    |
    5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium